Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1761 • ACR Convergence 2022
Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous studies suggest that seropositive and seronegative rheumatoid arthritis (RA) patients may respond differently to disease-modifying anti-rheumatic drugs (DMARDs). However, little is known about…
Abstract Number: 1955 • ACR Convergence 2022
Predictive Factor of Spontaneous Regression in Methotorexate-associated Lymphoproliferative Disorders with RA Patients
Tomohiro Kameda¹, shusaku nakashima², Masayuki Inoo³, Ikuko Onishi³, Noriyuki Kurata³, Hiromi Shimada¹, Risa Wakiya¹, Mikiya Kato¹, taichi miyagi⁴, Yusuke Ushio⁵, Rina Mino⁶, Kanako Chujo⁷, norimitsu Kadowaki⁸ and Hiroaki Dobashi⁹, ¹Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ³Utazu Hospital, Yayauta-gun, Japan, ⁴Kagawa University, Kidagun, Japan, ⁵Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ⁶Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan, ⁸Kagawa University, Kita-Gun, Japan, ⁹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan
Background/Purpose: Lymphoproliferative disorders (LPDs), including malignant lymphoma, are known to occur in RA patients treated with disease modified antirheumatic drugs (DMARDs). In particular, LPD associated…
Abstract Number: 1972 • ACR Convergence 2022
Comprehensive Investigation of Pain and Inflammation in Rheumatoid Arthritis from a Multidisciplinary Approach
Lilla Tóth¹, Gergely Orsi², Krisztina Csókási³, Gábor Sütő⁴, Gábor Kumánovics⁵, Noémi Császár-Nagy⁶, Szabolcs Takács⁷, Eszter Szigedi⁸, Zsófia Nagy⁸, Zsolt Hodovány⁸, Lili Duzsik⁸, Zoltán Vidnyánszky⁹, József Kun¹⁰, Péter Urbán¹⁰, György Nagy¹¹ and Zsuzsanna Helyes¹², ¹Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary, ²MTA-PTE Clinical Neuroscience MR Research Group, Eötvös Loránd Research Network (ELKH); Department of Neurology, Medical School, University of Pecs, Pécs, Hungary, ³Institute of Psychology, Faculty of Humanities and Social Sciences, University of Pécs, Pécs, Hungary, ⁴Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs, Pécs, Hungary, ⁵Department of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, ⁶National University of Public Services; Psychosomatic Outpatient Clinics, Budapest, Hungary, ⁷Department of Psychology, Karoly Gaspar University, Budapest, Hungary, ⁸Psychosomatic Outpatient Clinics, Budapest, Hungary, ⁹Brain Imaging Centre, Research Centre for Natural Sciences, Budapest, Hungary, ¹⁰Szentágothai Research Centre, Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, University of Pécs, Pécs, Hungary, ¹¹Department of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University; Department of Genetics, Cell and Immunobiology, Semmelweis University; Heart and Vascular Centre, Semmelweis University, Budapest, Hungary, ¹²Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs; Szentágothai Research Centre and Centre for Neuroscience, University of Pécs, Pécs, Hungary
Background/Purpose: Despite the therapeutic advances of rheumatoid arthritis (RA), optimal disease control cannot be achieved in the difficult-to-treat (D2T) RA population, leading to the persistence…
Abstract Number: 1990 • ACR Convergence 2022
Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients Who Will Respond or Be Refractory to Standard Biological Treatments
Giorgio CASABURI, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA
Background/Purpose: In recent years, biological therapies have revolutionized treatments of Rheumatoid Arthritis (RA). However, about 40% of RA patients do not respond to given biologics…
Abstract Number: 2006 • ACR Convergence 2022
Healthcare Resource Utilization and Economic Burden of Patients with Adequate and Inadequate Responses to Advanced Therapies for Rheumatoid Arthritis in Japan
Kei Ikeda¹, Yuko Kaneko², Jayeshkumar Patel³, Toru Yamazaki⁴, Siran Fang³, Tsujita Yuki⁴ and Yutaka Kawahito⁵, ¹Chiba University Hospital, Chiba, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie GK, Tokyo, Japan, ⁵Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan
Background/Purpose: Substantial numbers of patients with RA receiving advanced therapies including biologics, biosimilars, and Janus kinase inhibitors do not achieve ACR50 responses and lack of…
Abstract Number: 2187 • ACR Convergence 2022
Decision-Making Around Vaccination and Other Public Health Measures During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis
Jenny leese¹, Stephanie Therrien², Smruthi Ramachandran³, Catherine L. Backman³, Jasmin Ma⁴, Kelly English⁵, Eileen Davidson⁶, Shanon McQuitty⁷, Alison Hoens⁵, Cheryl Koehn⁸, James Gavin⁹, jo Adams⁹ and Linda Li³, ¹University of Ottawa, Ottawa, ON, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada/University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Patient Advisory Board of Arthritis Research Canada, Vancouver, BC, Canada, ⁶Arthritis Patient Advisory Board of Arthritis Research Canada, Burnaby, BC, Canada, ⁷Arthritis Patient Advisory Board of Arthritis Research Canada, Richmond, BC, Canada, ⁸Arthritis Consumer Experts, Vancouver, BC, Canada, ⁹University of Southampton, Southampton, United Kingdom
Background/Purpose: The spectrum of individual decisions about adopting public health measures (e.g., vaccination programs, physical distancing, mask wearing) to reduce COVID-19 transmission has important implications…
Abstract Number: 2251 • ACR Convergence 2022
Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Matthew Baker¹, Yuhan Liu¹, Rong Lu¹, Janice Lin¹, Jason Melehani¹ and William Robinson², ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…
Abstract Number: 0062 • ACR Convergence 2022
Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study
Justin Levinson¹, Jonathan Katz², Yi Chen³, W. Ryan Powell⁴, Andrea Gilmore-Bykovskyi⁵, Amy J. Kind⁶ and Christie Bartels⁷, ¹University of Wisconsin School of Medicine and Public Health, Department of Medicine, Rheumatology Division, Madison, WI, ²University of Wisconsin Hospitals and Clinics, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Department of Medicine, Department of Biostatistics and Informatics, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, ⁵University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, ⁶University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, ⁷University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Chronic inflammatory diseases have been associated with an increased risk of Alzheimer’s disease (AD), yet emerging research in rheumatoid arthritis (RA) and psoriasis suggests…
Abstract Number: 0121 • ACR Convergence 2022
Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Treatment Guidelines
Megan Thomas¹, Cheryl Barnabe², Tessa Kleissen², Diane Lacaille³, Glen Hazlewood², Nejat Hassen⁴, Richard Henry⁵, Kelly English⁶, Michael Kuluva⁷, Aurore Fifi-Mah² and Nicole Johnson², ¹University of British Columbia, Vancouver, BC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Arthritis Research Canada, RICHMOND, BC, Canada, ⁵McGill University, Montréal, QC, Canada, ⁶Arthritis Patient Advisory Board of Arthritis Research Canada, Vancouver, BC, Canada, ⁷Creaky Joints, Vancouver, BC, Canada
Background/Purpose: Guidelines may unintentionally introduce inequities in care through recommendations that do not reflect the realities of healthcare access and quality for persons who are…
Abstract Number: 0243 • ACR Convergence 2022
Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study
Naohiro Sugitani¹, Eiichi Tanaka¹, Eisuke Inoue², Kotaro Watanabe³, Mai Abe³, Eri Sugano³, Kumiko Saka³, Moeko Ochiai³, Rei Yamaguchi³, Katsunori Ikari⁴ and Masayoshi Harigai¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Research Administration Center, Showa University, Shinagawa-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Japan, ⁴Department of Orthopedic Surgery, Tokyo Women’s Medial University School of Medicine, Shinjuku, Japan
Background/Purpose: The number of elderly patients with rheumatoid arthritis (RA) has been constantly increasing. As of December 2021, 50.3% of the patients with RA who…
Abstract Number: 0259 • ACR Convergence 2022
Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA
Ju Yeon Kim¹, Kichul Shin², Eun Bong Lee¹ and Jun Won Park¹, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: This study aims to evaluate the impact of comorbidities on disease activity and functional disability in patients with RA treated with biological disease-modifying anti-rheumatic…
Abstract Number: 0276 • ACR Convergence 2022
Baseline Characteristics of and Early Outcomes in the First 200 Patients with RA Treated with Filgotinib in a Prospective Observational Study
James Galloway¹, Karen Bevers², Patrick Verschueren³, Roberto Felice Caporali⁴, Susana Romero Yuste⁵, Jérôme Avouac⁶, Emilia Gvozdenovic⁷, Kristina Harris⁷, Monia Zignani⁷ and Gerd Burmester⁸, ¹King's College London, London, United Kingdom, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³University Hospital Leuven, Leuven, Belgium, ⁴University of Milan, Milano, Italy, ⁵Complexo Hospitalario Universitario, Pontevedra, Spain, ⁶University of Paris, Paris, France, ⁷Galapagos NV, Mechelen, Belgium, ⁸Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is a preferential Janus kinase 1 inhibitor, approved in Europe for the treatment of RA and ulcerative colitis. A phase 4 European…
Abstract Number: 0293 • ACR Convergence 2022
Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND
Ronald van Vollenhoven¹, Stephen Hall², Alvin Wells³, Sebastian Meerwein⁴, Yanna Song⁵, Jessica Suboticki⁶ and Roy Fleischmann⁷, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Emeritus Research and Monash University, Melbourne, Australia, ³Aurora Rheumatology and Immunotherapy Center, Franklin, WI, ⁴AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment goal for patients with rheumatoid arthritis (RA) is sustained remission (REM), but low disease activity (LDA) is considered an appropriate target…
Abstract Number: 0311 • ACR Convergence 2022
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zunsemetinib, an Investigational Oral MK2 Inhibitor, at 80 Mg and 120 Mg Twice Daily Dose Levels in Healthy Subjects
Ajay Aggarwal¹, David Burt², Laura Connelly², Joseph Monahan² and Jessea Lu², ¹Aclaris Therapeutics, Wellesley, MA, ²Aclaris Therapeutics, Inc., Wayne, PA
Background/Purpose: Zunsemetinib is an orally available potent and selective small molecule inhibitor of the p38α MAPK/MK2 signaling axis. Aclaris Therapeutics, Inc. is developing zunsemetinib for…
Abstract Number: 0533 • ACR Convergence 2022
Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity
Timothy Wilson¹, Jacob Welch², Marie Feser², Elizabeth Bemis², Claudia Lugo², Gary S. Firestein³, Thomas F. Bumol⁴, Jill Norris⁵, V. Michael Holers⁶, Kevin D Deane⁷ and Kristen Demoruelle², ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of California, San Diego, San Diego, CA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Aurora, CO, ⁶University of Colorado, Denver, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Denver, CO
Background/Purpose: Presence of systemic anti-CCP-IgG antibodies in individuals without inflammatory arthritis (IA) strongly predicts developing future classified RA. However, published data also demonstrate that 50-70%…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].